GW-0742 vs Cardarine

GW-0742 wins for sheer potency, cleaner per-mg activation of PPARδ, and applications where maximal fat oxidation or endurance drive matter most.

Cardarine wins for widespread availability, much longer human data history, lower per-mg cost, and a (relatively) more robust safety record on standard-length protocols. Both have similar cycle-length constraints due to rodent cancer data, but Cardarine remains better-characterized in practice.

Pick GW-0742 if:

• Maximal PPARδ activation is required — e.g., competitive endurance phases or advanced recomp with stubborn fat.
• Research calls for lower mg-per-day dosing with higher receptor binding.
• Prior Cardarine protocols felt underwhelming at standard doses.
• Sourcing and authenticity are not a limiting factor (lab-verified GW-0742 is less widely available).
• The focus is on stacking with SARMs or orals where every mg counts for lipid correction or fat oxidation.

Pick Cardarine if:

• Reliance on community-vetted protocols and larger real-world sample size is preferred.
• Easy sourcing and product verification matter more than absolute potency.
• Standard endurance, conditioning, or lipid management goals without needing to push dosing boundaries.
• Cost-per-cycle is a concern.
• Long track record of practical stacking with SARMs, orals, or as a stand-alone fat-loss modulator.